Alnylam Pharmaceuticals Inc (ALNY) — Financial Flexibility Index
Alnylam Pharmaceuticals Inc (ALNY) has a Financial Flexibility Index of 0.04x as of December 2025. Free cash flow of $186.85 Million (operating CF $163.56 Million minus capex $23.29 Million) represents 0% of total liabilities ($4.18 Billion). Check ALNY capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Alnylam Pharmaceuticals Inc Financial Flexibility Index (2002–2025)
Historical Financial Flexibility Index trend for Alnylam Pharmaceuticals Inc across 24 annual periods. See Alnylam Pharmaceuticals Inc (ALNY) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Alnylam Pharmaceuticals Inc (2002–2025)
Year-by-year free cash flow to debt coverage for Alnylam Pharmaceuticals Inc. For the full company profile including market capitalisation, see how much is Alnylam Pharmaceuticals Inc worth.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.14x | $582.78 Million | $524.08 Million | $4.18 Billion | ▲ +2142.2% |
| 2024 | 0.01x | $25.96 Million | $-8.31 Million | $4.17 Billion | ▼ -84.9% |
| 2023 | 0.04x | $166.37 Million | $104.16 Million | $4.05 Billion | ▲ +132.4% |
| 2022 | -0.13x | $-469.21 Million | $-541.27 Million | $3.70 Billion | ▲ +31.6% |
| 2021 | -0.19x | $-565.32 Million | $-641.69 Million | $3.06 Billion | ▲ +18.8% |
| 2020 | -0.23x | $-544.60 Million | $-614.96 Million | $2.39 Billion | ▼ -57.6% |
| 2019 | -0.14x | $-138.27 Million | $-278.43 Million | $956.44 Million | ▲ +90.9% |
| 2018 | -1.60x | $-435.73 Million | $-562.62 Million | $272.84 Million | ▼ -30.9% |
| 2017 | -1.22x | $-278.58 Million | $-382.79 Million | $228.30 Million | ▼ -71.9% |
| 2016 | -0.71x | $-243.14 Million | $-307.70 Million | $342.59 Million | ▲ +50.9% |
| 2015 | -1.45x | $-176.19 Million | $-189.14 Million | $121.80 Million | ▼ -32.3% |
| 2014 | -1.09x | $-156.68 Million | $-165.64 Million | $143.33 Million | ▼ -153.9% |
| 2013 | -0.43x | $-64.65 Million | $-68.66 Million | $150.18 Million | ▲ +38.4% |
| 2012 | -0.70x | $-107.26 Million | $-115.61 Million | $153.47 Million | ▼ -33.6% |
| 2011 | -0.52x | $-85.78 Million | $-87.07 Million | $163.92 Million | ▼ -54.5% |
| 2010 | -0.34x | $-79.61 Million | $-84.34 Million | $235.03 Million | ▼ -52.9% |
| 2009 | -0.22x | $-67.20 Million | $-72.14 Million | $303.42 Million | ▼ -202.4% |
| 2008 | 0.22x | $76.25 Million | $65.49 Million | $352.55 Million | ▼ -68.8% |
| 2007 | 0.69x | $204.31 Million | $196.52 Million | $294.62 Million | ▲ +237.1% |
| 2006 | -0.51x | $-19.64 Million | $-24.63 Million | $38.83 Million | ▼ -27.2% |
| 2005 | -0.40x | $-14.54 Million | $-16.48 Million | $36.57 Million | ▲ +24.9% |
| 2004 | -0.53x | $-10.56 Million | $-19.57 Million | $19.96 Million | ▼ -237.3% |
| 2003 | -0.16x | $-9.71 Million | $-12.83 Million | $61.89 Million | ▼ -354.8% |
| 2002 | -0.03x | $-716.00K | $-1.28 Million | $20.76 Million | — |